Urologix Valuation
| ULGXDelisted Stock | USD 0.0001 0.00 0.00% |
Urologix seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Urologix from inspecting the company fundamentals such as Return On Asset of -0.0762, number of shares shorted of 41.23 K, and Current Valuation of 4.92 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Urologix's price fluctuation is very steady at this time. Calculation of the real value of Urologix is based on 3 months time horizon. Increasing Urologix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Urologix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Urologix Pink Sheet. However, Urologix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.5E-5 | Hype 1.0E-4 |
The intrinsic value of Urologix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Urologix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Urologix helps investors to forecast how Urologix pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Urologix more accurately as focusing exclusively on Urologix's fundamentals will not take into account other important factors: Urologix Total Value Analysis
Urologix is at this time forecasted to have valuation of 4.92 M with market capitalization of 82.91 K, debt of 4.59 M, and cash on hands of 492 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Urologix fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.92 M | 82.91 K | 4.59 M | 492 K |
Urologix Investor Information
The company recorded a loss per share of 0.22. Urologix had not issued any dividends in recent years. Based on the key measurements obtained from Urologix's financial statements, Urologix is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Urologix Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Urologix has an asset utilization ratio of 247.26 percent. This suggests that the Company is making $2.47 for each dollar of assets. An increasing asset utilization means that Urologix is more efficient with each dollar of assets it utilizes for everyday operations.Urologix Profitability Analysis
The company reported the previous year's revenue of 14.01 M. Net Loss for the year was (7.61 M) with profit before overhead, payroll, taxes, and interest of 5.9 M.About Urologix Valuation
Our relative valuation model uses a comparative analysis of Urologix. We calculate exposure to Urologix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Urologix's related companies.Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. UROLOGIX operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 61 people.
8 Steps to conduct Urologix's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Urologix's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Urologix's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Urologix's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Urologix's revenue streams: Identify Urologix's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Urologix's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Urologix's growth potential: Evaluate Urologix's management, business model, and growth potential.
- Determine Urologix's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Urologix's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Urologix Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Retained Earnings | -126.6 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Urologix Pink Sheet
If you are still planning to invest in Urologix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Urologix's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |